AutoGenomics, Inc. Files Registration Statement for Initial Public Offering
Carlsbad, CA, July 25, 2008 - AutoGenomics, Inc. today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. The number of shares of common stock to be offered, all of which are expected to be offered by AutoGenomics, Inc., and the price range for the offering, have not yet been determined.
J.P. Morgan Securities Inc. is acting as sole book-running manager of the offering, and Deutsche Bank Securities Inc. is acting as co-lead manager. Pacific Growth Equities, LLC and Robert W. Baird & Co. Incorporated are acting as co-managers.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this offering may be obtained by contacting: J.P. Morgan Securities Inc., 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 Attention: Chase Distribution & Support Service Northeast Statement Processing.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state.
AutoGenomics Inc., a privately held company based in Carlsbad, CA, has developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed leading to the era of personalized medicine. For more information, please visit www.autogenomics.com
For further information please contact:
Thomas V. Hennessey, Jr.
Chief Operating Officer and Chief Financial Officer, AutoGenomics